Recordati stock holds above tender offer price as investors weigh CVC-GBL bid
Published on 08/29/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Recordati (ISIN IT0003828271) stock is trading just above the EUR51.29 per-share tender offer price in late August 2026, underscoring investors' confidence in the pending bid to take the Italian pharmaceutical group private as of August 28, 2026.
The upcoming voluntary tender offer by a CVC-led consortium, acting through Respighi BidCo and backed by GBL, is scheduled to run from August 31 to October 15, 2026, with settlement set for October 23, 2026, giving Recordati shareholders a defined window to decide whether to tender their shares.
For investors, the combination of a premium-priced bid and solid first quarter 2026 earnings creates a structured scenario where fundamental strength and deal certainty both matter for Recordati stock.
Bid details and market pricing
Respighi BidCo has confirmed that the tender offer for Recordati ordinary shares will be launched at a cash consideration of EUR51.29 per share, following approval of the offer document by the Italian securities regulator Consob and the company board's assessment that the price is fair in light of available information. The tender offer timetable and price were outlined in a detailed private equity report.
According to this offer timetable, shareholders will be able to tender Recordati shares from August 31 to October 15, 2026, with payment of the EUR51.29 per-share consideration planned for October 23, 2026, and a possible subsequent reopening period from October 26 to October 30, 2026.
Market data cited in the same context indicate that Recordati stock closed at EUR51.40 on August 27, 2026, a modest EUR0.11 above the tender offer price, suggesting that traders continue to assign a high probability to deal completion rather than a significantly higher competing bid at this stage.
First quarter 2026 earnings support the valuation
The valuation underpinning the tender offer is reinforced by Recordati's strong operational performance in the first quarter of 2026, which saw double-digit growth across key financial metrics compared with the prior-year period.
In Q1 2026, Recordati generated revenues of EUR714.4 million, delivering robust top-line momentum that provides an earnings base for the offer valuation and signals solid demand for the company’s portfolio of specialty and rare disease therapies. The same investor presentation summary reports Q1 2026 revenue at EUR714.4 million.
Alongside revenue growth, Recordati reported Q1 2026 EBITDA of EUR283.6 million, pointing to a healthy earnings capacity that supports the bid multiple and underlines the cash-generating nature of the business.
Adjusted net income for the quarter reached EUR188.3 million, highlighting that profitability remains robust; compared with prior quarters, this level of earnings confirms that Recordati is entering the tender offer period from a position of strength rather than weakness.
Historically, Recordati’s earlier annual and interim reports had already shown resilience, but the Q1 2026 figures are particularly important because they fall inside the current freshness window for fundamental data relative to late August 2026.
CVC-GBL consortium builds its stake
The bid for Recordati also reflects an extended period of stake-building by the CVC-GBL consortium, which has been acquiring shares on the market in parallel with the formal offer process.
As of May 22, 2026, GBL had accumulated a direct stake of 3.25 percent in Recordati through multiple share purchases, demonstrating long-term commitment to the pharmaceutical group and aligning interests with the planned delisting strategy. This stake-building activity was highlighted in a corporate news overview of GBL holdings.
At the same time, the wider consortium led by CVC has moved toward full control through the Respighi BidCo vehicle, with the tender offer designed to secure all outstanding Recordati shares and ultimately remove the company from public listing.
The EUR51.29 per-share offer price, validated by the Recordati board as fair, positions the bid at a level that was only slightly below the trading price in recent sessions, suggesting that the market expects the deal to close without a significant improvement in terms.
Deal premium and trading dynamics
From a market perspective, the fact that Recordati stock is trading marginally above the offer price conveys a nuanced investor view: the spread between the EUR51.40 closing price on August 27, 2026, and the EUR51.29 offer price is small, indicating confidence in the bid while also leaving limited room for speculation on a higher counteroffer.
The limited premium over the tender price implies that arbitrage-oriented investors may see the situation as largely priced in, with the main residual risk focused on regulatory or procedural aspects rather than fundamental valuation or competing cash offers.
For longer-term shareholders who have benefited from Recordati's earnings growth, the bid crystallizes value in cash terms while also ending participation in future upside that could arise from continued expansion in its core therapeutic areas.
Representative product: rare disease portfolio
Recordati’s business model is anchored in specialty and rare disease treatments, where targeted therapies can deliver meaningful clinical benefits and sustainable pricing power.
A representative example is the company’s focus on rare disease medications across endocrinology and cardiology, which supports both revenue growth and margin resilience as reflected in the EUR714.4 million Q1 2026 revenue figure and the EUR283.6 million EBITDA reported for the same period.
These types of therapies are central to the strategic appeal of Recordati for private equity investors, as they combine relatively predictable cash flows with the potential for pipeline-driven expansion and geographic diversification.
Recordati stock and investor takeaway
Recordati stock, quoted at EUR51.40 on August 27, 2026, stands just above the EUR51.29 tender offer level, underscoring that deal expectations now largely drive price behavior alongside the company’s strong Q1 2026 financials.
For investors, the key question is whether to lock in the cash consideration during the tender period or retain exposure in the hope of a competing bid, but the narrow gap between market price and offer level suggests that the consensus view currently favors acceptance of the existing deal terms.
Fact box
Company: Recordati S.p.A.
ISIN: IT0003828271
Ticker: not specified
Exchange: Borsa Italiana
Price (as of August 27, 2026): EUR51.40
Sector / Industry: Pharmaceuticals
Index membership: not specified
